GB0326148D0 - Morpholine derivatives - Google Patents

Morpholine derivatives

Info

Publication number
GB0326148D0
GB0326148D0 GBGB0326148.4A GB0326148A GB0326148D0 GB 0326148 D0 GB0326148 D0 GB 0326148D0 GB 0326148 A GB0326148 A GB 0326148A GB 0326148 D0 GB0326148 D0 GB 0326148D0
Authority
GB
United Kingdom
Prior art keywords
morpholine derivatives
morpholine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0326148.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0326148(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to GBGB0326148.4A priority Critical patent/GB0326148D0/en
Publication of GB0326148D0 publication Critical patent/GB0326148D0/en
Priority to TW093132096A priority patent/TWI339658B/zh
Priority to DE602004028750T priority patent/DE602004028750D1/de
Priority to NZ546067A priority patent/NZ546067A/en
Priority to DK04794209.9T priority patent/DK1682523T3/da
Priority to EA200600945A priority patent/EA009960B1/ru
Priority to CN2004800331155A priority patent/CN1878762B/zh
Priority to PL04794209T priority patent/PL1682523T3/pl
Priority to EP10162865A priority patent/EP2223916A1/en
Priority to CA2544649A priority patent/CA2544649C/en
Priority to JP2006539492A priority patent/JP4850068B2/ja
Priority to SI200431540T priority patent/SI1682523T1/sl
Priority to UAA200604519A priority patent/UA85198C2/ru
Priority to US10/577,841 priority patent/US7423037B2/en
Priority to AU2004289616A priority patent/AU2004289616B2/en
Priority to PCT/US2004/032771 priority patent/WO2005047272A1/en
Priority to KR1020067008999A priority patent/KR100783855B1/ko
Priority to BRPI0415273A priority patent/BRPI0415273B8/pt
Priority to AT04794209T priority patent/ATE478057T1/de
Priority to PT04794209T priority patent/PT1682523E/pt
Priority to ES04794209T priority patent/ES2348872T3/es
Priority to EP04794209A priority patent/EP1682523B1/en
Priority to MYPI20044640A priority patent/MY141048A/en
Priority to ARP040104126A priority patent/AR046927A1/es
Priority to PE2004001093A priority patent/PE20050491A1/es
Priority to SV2004001934A priority patent/SV2006001934A/es
Priority to IL175365A priority patent/IL175365A/he
Priority to EC2006006555A priority patent/ECSP066555A/es
Priority to ZA200603680A priority patent/ZA200603680B/en
Priority to CR8390A priority patent/CR8390A/es
Priority to MA29074A priority patent/MA28330A1/fr
Priority to NO20062700A priority patent/NO336268B1/no
Priority to HK07100215.2A priority patent/HK1095135A1/xx
Priority to HR20100476T priority patent/HRP20100476T1/hr
Priority to CY20101100858T priority patent/CY1110796T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0326148.4A 2003-11-10 2003-11-10 Morpholine derivatives Ceased GB0326148D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives
TW093132096A TWI339658B (en) 2003-11-10 2004-10-22 Morpholine derivatives as norepinephrine reuptake inhibitors
ES04794209T ES2348872T3 (es) 2003-11-10 2004-10-28 Derivados de morfolina como inhibidores de la recaptacion de norepinefrina.
EP04794209A EP1682523B1 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
PCT/US2004/032771 WO2005047272A1 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
PT04794209T PT1682523E (pt) 2003-11-10 2004-10-28 Derivados de morfolina como inibidores da recaptação de norepinefrina
DK04794209.9T DK1682523T3 (da) 2003-11-10 2004-10-28 Morpholin-derivater som noradrenalin-genoptagelsesinhibitorer
EA200600945A EA009960B1 (ru) 2003-11-10 2004-10-28 Производные морфолина в качестве ингибиторов повторного захвата норадреналина
CN2004800331155A CN1878762B (zh) 2003-11-10 2004-10-28 作为去甲肾上腺素再摄取抑制剂的吗啉衍生物
PL04794209T PL1682523T3 (pl) 2003-11-10 2004-10-28 Pochodne morfoliny jako inhibitory wychwytu zwrotnego noradrenaliny
EP10162865A EP2223916A1 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
CA2544649A CA2544649C (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
JP2006539492A JP4850068B2 (ja) 2003-11-10 2004-10-28 ノルエピネフリン再取り込み阻害剤としてのモルホリン誘導体
SI200431540T SI1682523T1 (sl) 2003-11-10 2004-10-28 Derivati morfolina kot inhibitorji ponovnega prevzema norepinefrina
UAA200604519A UA85198C2 (ru) 2003-11-10 2004-10-28 Производные морфолина как ингибиторы повторного поглощения норэпинефрина
US10/577,841 US7423037B2 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
AU2004289616A AU2004289616B2 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors
DE602004028750T DE602004028750D1 (de) 2003-11-10 2004-10-28 Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
KR1020067008999A KR100783855B1 (ko) 2003-11-10 2004-10-28 노르에피네프린 재흡수 억제제로서의 모르폴린 유도체
BRPI0415273A BRPI0415273B8 (pt) 2003-11-10 2004-10-28 derivados de morfolina como inibidores de reabsorção de norepinefrina, seu sal de cloridrato, seu uso, seus intermediários e seu processo de preparação, e composição farmacêutica
AT04794209T ATE478057T1 (de) 2003-11-10 2004-10-28 Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
NZ546067A NZ546067A (en) 2003-11-10 2004-10-28 Morpholine derivatives such as 2-[5-fluoro-2-methyloxy)phenyl]-1-morpholin-2-yl-1-tetrahydro-2H-pyran-4-ylethanol as norepinephrine reuptake inhibitors
MYPI20044640A MY141048A (en) 2003-11-10 2004-11-08 Morpholine derivatives as norepinephrine reuptake inhibitors
ARP040104126A AR046927A1 (es) 2003-11-10 2004-11-09 Derivados de morfolina como inhibidores de la recaptacion de norepinefrina
PE2004001093A PE20050491A1 (es) 2003-11-10 2004-11-09 Derivados de morfolina como inhibidores de la recaptacion de norepinefrina
SV2004001934A SV2006001934A (es) 2003-11-10 2004-11-10 Derivados de morfolina como inhibidores de la recaptacion de norepinefrina ref. x-15830
IL175365A IL175365A (he) 2003-11-10 2006-05-01 נגזרות של מורפולין,תכשירים רפואיים המכילים אותן ושימושן בהכנת תרופות
EC2006006555A ECSP066555A (es) 2003-11-10 2006-05-09 Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina
ZA200603680A ZA200603680B (en) 2003-11-10 2006-05-09 Morpholine derivatives as norepinephrine reuptake inhibitors
CR8390A CR8390A (es) 2003-11-10 2006-05-10 Derivados de morfolina como inhibidores de la reabsorcion de norepinefrina
MA29074A MA28330A1 (fr) 2003-11-10 2006-06-02 Derives de morpholine en tant qu'inhibiteurs de la recapture de la norepinephrine
NO20062700A NO336268B1 (no) 2003-11-10 2006-06-12 Morfolinderivater som norepinefringjenopptakingsinhibitorer
HK07100215.2A HK1095135A1 (en) 2003-11-10 2007-01-05 Morpholine derivatives as norepinephrine reuptake inhibitors
HR20100476T HRP20100476T1 (hr) 2003-11-10 2010-08-31 Morfolinski derivati kao inhibitori povratnog unosa noradrenalina
CY20101100858T CY1110796T1 (el) 2003-11-10 2010-09-23 Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives

Publications (1)

Publication Number Publication Date
GB0326148D0 true GB0326148D0 (en) 2003-12-17

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0326148.4A Ceased GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives

Country Status (34)

Country Link
US (1) US7423037B2 (he)
EP (2) EP1682523B1 (he)
JP (1) JP4850068B2 (he)
KR (1) KR100783855B1 (he)
CN (1) CN1878762B (he)
AR (1) AR046927A1 (he)
AT (1) ATE478057T1 (he)
AU (1) AU2004289616B2 (he)
BR (1) BRPI0415273B8 (he)
CA (1) CA2544649C (he)
CR (1) CR8390A (he)
CY (1) CY1110796T1 (he)
DE (1) DE602004028750D1 (he)
DK (1) DK1682523T3 (he)
EA (1) EA009960B1 (he)
EC (1) ECSP066555A (he)
ES (1) ES2348872T3 (he)
GB (1) GB0326148D0 (he)
HK (1) HK1095135A1 (he)
HR (1) HRP20100476T1 (he)
IL (1) IL175365A (he)
MA (1) MA28330A1 (he)
MY (1) MY141048A (he)
NO (1) NO336268B1 (he)
NZ (1) NZ546067A (he)
PE (1) PE20050491A1 (he)
PL (1) PL1682523T3 (he)
PT (1) PT1682523E (he)
SI (1) SI1682523T1 (he)
SV (1) SV2006001934A (he)
TW (1) TWI339658B (he)
UA (1) UA85198C2 (he)
WO (1) WO2005047272A1 (he)
ZA (1) ZA200603680B (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (he) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU9214498A (en) 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
JP2002501025A (ja) * 1998-01-21 2002-01-15 グラクソ グループ リミテッド 薬学的に活性なモルホリノール
WO2001000214A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
CN1660108A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) * 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TW200524885A (en) 2005-08-01
NZ546067A (en) 2009-04-30
US20070083046A1 (en) 2007-04-12
KR20060086408A (ko) 2006-07-31
CN1878762A (zh) 2006-12-13
PT1682523E (pt) 2010-09-20
AU2004289616B2 (en) 2010-08-05
BRPI0415273A (pt) 2006-12-19
AU2004289616A1 (en) 2005-05-26
MA28330A1 (fr) 2006-12-01
HK1095135A1 (en) 2007-04-27
ZA200603680B (en) 2007-07-25
CA2544649A1 (en) 2005-05-26
CR8390A (es) 2007-12-07
BRPI0415273B1 (pt) 2019-04-30
BRPI0415273B8 (pt) 2021-05-25
IL175365A0 (en) 2006-09-05
PE20050491A1 (es) 2005-08-24
WO2005047272A1 (en) 2005-05-26
SV2006001934A (es) 2006-02-15
US7423037B2 (en) 2008-09-09
DE602004028750D1 (de) 2010-09-30
JP2007510720A (ja) 2007-04-26
AR046927A1 (es) 2006-01-04
EP1682523B1 (en) 2010-08-18
KR100783855B1 (ko) 2007-12-10
CA2544649C (en) 2012-08-14
TWI339658B (en) 2011-04-01
CY1110796T1 (el) 2015-06-10
PL1682523T3 (pl) 2011-01-31
MY141048A (en) 2010-02-25
HRP20100476T1 (hr) 2010-10-31
IL175365A (he) 2011-02-28
ATE478057T1 (de) 2010-09-15
EP2223916A1 (en) 2010-09-01
CN1878762B (zh) 2010-10-27
EP1682523A1 (en) 2006-07-26
ES2348872T3 (es) 2010-12-16
UA85198C2 (ru) 2009-01-12
SI1682523T1 (sl) 2010-12-31
JP4850068B2 (ja) 2012-01-11
EA200600945A1 (ru) 2006-10-27
EA009960B1 (ru) 2008-04-28
ECSP066555A (es) 2006-10-17
NO20062700L (no) 2006-08-08
DK1682523T3 (da) 2010-11-15
NO336268B1 (no) 2015-07-06

Similar Documents

Publication Publication Date Title
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
TWI349666B (en) Substituted morpholine and thiomorpholine derivatives
AP1850A (en) Spiroindolineplperidine derivatives
GB0202015D0 (en) Piperazine Derivatives
LT3002283T (lt) Tiazolo dariniai
TWI347187B (en) Pyrido-and pyrimidopyrimidine derivatives
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
TWI368482B (en) New 2-pyridinylethylbenzamide derivatives
ZA200506744B (en) PyrazoloÄ1,5-AÜpyrimidine derivatives
EP1689395A4 (en) DERIVATIVES OF THE PERVENCHE
PT1706373E (pt) Derivados de amidoacetonitrilo
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0219687D0 (en) Benzyl morpholine derivatives
GB0326148D0 (en) Morpholine derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
GB0319148D0 (en) Azaquinazoline derivatives
AU2003280822A8 (en) Beauveriolide derivatives
GB0219685D0 (en) Benzyl morpholine derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)